Earnings Report Digest
$ABT has released its Q2 2025 earnings, where EPS of $1.26 met expectations while revenue reached $11.14B, reflecting a 7.37% year-over-year increase. Despite a 1.5% decline in diagnostics sales, particularly in COVID testing, other divisions showed resilience with medical devices growing by 12%. Key risks include ongoing headwinds from COVID impacts and geopolitical issues in China. Future opportunities hinge on product advancements, especially in diabetes care and biosimilars. đâš For more details, check valueverge.com/ABT.
469 episoder
Kommentarer
0VĂŠr den fĂžrste til at kommentere
Tilmeld dig nu og bliv en del af Earnings Report Digest-fĂŠllesskabet!